The port delivery system with ranibizumab: understanding nuances for clinical use in the real world

Expert Opin Biol Ther. 2022 Jun;22(6):675-677. doi: 10.1080/14712598.2022.2078162. Epub 2022 May 23.

Authors

Ashish Sharma¹, Nikulaa Parachuri^{1

2}, Nilesh Kumar^{1

3}, Baruch D Kuppermann⁴, Francesco Bandello⁵, Carl D Regillo⁶

Affiliations

¹ Lotus Eye Hospital and Institute, Coimbatore, India.
² Department of Vitreoretina, Sankara Eye Hospital, Coimbatore, India.
³ Madhavi Netralaya, Ara, India.
⁴ Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA.
⁵ University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy.
⁶ The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania, USA.

PMID: 35549582
DOI: 10.1080/14712598.2022.2078162

No abstract available

Keywords: PDS; anti-VEGF; nAMD; real world.

Publication types

Editorial

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Humans
Intravitreal Injections
Ranibizumab* / therapeutic use
Recombinant Fusion Proteins
Retrospective Studies
Wet Macular Degeneration* / drug therapy

Substances

Angiogenesis Inhibitors
Recombinant Fusion Proteins
Ranibizumab